stock delisting
Nasdaq Panel Delisting T2 Biosystems Stock
The company was in violation of the stock exchange's requirements for the minimum bid price and the market value of listed securities.
In Brief This Week: Beckman Coulter, Quest Diagnostics, Guardant Health, Diasorin, More
News items for the week of Jan. 27, 2025.
Aspira Receives Delisting Notice, Announces Plans to Appeal the Decision
The firm received notice that it had failed to regain compliance with the Nasdaq's requirement to maintain a minimum $35 million market value of listed securities.
Nasdaq Affirms OpGen's Delisting Decision
The molecular diagnostics developer has appealed the decision and said its stock will continue to trade on the OTC markets in the meantime.
T2 Biosystems Receives Delisting Notice From Nasdaq
The company has requested a hearing and paid a $20,000 fee to delay its delisting determination until Jan. 9, 2025.
Nov 7, 2024
Trinity Biotech Regains Nasdaq Compliance
Aug 23, 2024
OpGen Shares Suspended From Trading on Nasdaq
Apr 24, 2024
Nasdaq Warns OpGen About Overdue 2023 Annual Report
Apr 17, 2024
DermTech Receives Delisting Warning From Nasdaq
Jan 7, 2024
LumiraDx Shares to be Delisted From Nasdaq
Jan 4, 2024
Burning Rock Receives Nasdaq Delisting Warning
Jan 3, 2024
360Dx Top 30 Falls 5 Percent in 2023
Dec 13, 2023
OpGen Requests Hearing on Nasdaq Delisting
Nov 27, 2023
T2 Biosystems Receives Nasdaq Delisting Notice
Sep 25, 2023
Invitae Warned by NYSE of Noncompliance
May 5, 2023